Program to reduce unnecessary medications for patients with chronic kidney disease
Development and Evaluation of a Multidisciplinary Team Delivered Deprescribing Intervention for Patients With Chronic Kidney Disease in Qatar: A Randomized Controlled Trial
This study is testing a program that helps people with chronic kidney disease in Qatar reduce unnecessary medications to see if it improves their health and quality of life.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 424 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hamad Medical Corporation Industry-sponsored |
| Locations | 1 site (Doha) |
| Trial ID | NCT06324045 on ClinicalTrials.gov |
What this trial studies
This program aims to address the issue of polypharmacy among patients with chronic kidney disease (CKD) in Qatar by implementing a multidisciplinary deprescribing intervention. The approach involves systematically stopping or adjusting medications to improve clinical outcomes and reduce treatment burden. The study will evaluate the effectiveness of this intervention on patient health and quality of life, while also conducting a cost-benefit analysis to assess its economic viability for healthcare systems. By focusing on a collaborative approach, the program seeks to provide strong evidence for the benefits of deprescribing in CKD management.
Who should consider this trial
Good fit: Ideal candidates for this program are patients diagnosed with end-stage renal disease receiving hemodialysis or pre-dialysis patients followed at a low clearance clinic in Qatar.
Not a fit: Patients who are critically ill, have psychiatric conditions, or a limited life expectancy of less than six months may not benefit from this program.
Why it matters
Potential benefit: If successful, this program could significantly improve the quality of life and clinical outcomes for patients with chronic kidney disease by reducing medication burden.
How similar studies have performed: Previous deprescribing initiatives have shown promise in managing polypharmacy in chronic conditions, but this specific multidisciplinary approach is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients who are: * diagnosed with ESRD receiving hemodialysis treatment or pre-dialysis patients who are followed up at a low clearance clinic. * receiving treatment at one of the ambulatory kidney centers in Qatar for at least two months. * able to communicate in Arabic and/or English. Exclusion Criteria: * Unstable or has a psychiatric condition. * Presents with uncontrolled behaviors or exit-seeking behaviors (i.e., seeking to leave the premises out of confusion, frustration, or anger). * Critically ill patients, pregnant women, children, mentally ill, dementia, and unconscious patients. * Patients with limited life expectancy (less than 6 months).
Where this trial is running
Doha
- Hamad Medical Corporation — Doha, Qatar (Recruiting)
Study contacts
- Study coordinator: Abdullah Hamad, MD
- Email: Ahamad9@hamad.qa
- Phone: +97444394888
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.